$PTHS
Channel Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.
Healthcare
Sector
Biotechnology
Industry
Francis Knuettel II,
CEO
4
Employees
$27.17
Current Price
$8.90M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 1 | $40,264.95 | 1,500 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 1 | $40,264.95 | 1,500 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 4 | 7 | $85,044.79 | 3,641 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 4 | 7 | $85,044.79 | 3,641 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| May 22, 2026 | Francis Knuettel II CFO, Treas & Secty | Sale | 1,500 | $26.84 | $40,264.95 | View Details |
| Apr 2, 2026 | Friedberg Ezra M Director | Sale | 293 | $20.51 | $6,010.05 | View Details |
| Apr 2, 2026 | Friedberg Ezra M Director | Sale | 265 | $21.36 | $5,660.72 | View Details |
| Apr 2, 2026 | Pauls Matthew Director | Sale | 371 | $21.36 | $7,925.60 | View Details |
| Apr 2, 2026 | Pauls Matthew Director | Sale | 415 | $20.52 | $8,513.89 | View Details |
| Apr 2, 2026 | Greenleaf Peter Director | Sale | 377 | $21.36 | $8,053.25 | View Details |
| Apr 2, 2026 | Greenleaf Peter Director | Sale | 420 | $20.52 | $8,616.34 | View Details |
4 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
EPS
Estimated-$3.84
ActualN/A
Revenue
Estimated$9.09M
ActualN/A
EPS
Estimated-$3.70
Actual-$6.87
Miss
Revenue
Estimated$9.09M
Actual$9.39M
Beat
2 more earnings records available โ create a free account to see 12 months of history